<DOC>
	<DOCNO>NCT01888458</DOCNO>
	<brief_summary>Infections due post transplant immune deficiency major problem follow allogeneic stem cell transplantation ( Allo-SCT ) , particularly patient receive cord blood transplant ( CB ) . Duration neutropenia one important risk factor invasive fungal infection ( IFI ) . In set , Micafungin approve antifungal prophylaxis patient undergoing Allo-SCT . In randomized , double-blind , comparative , phase III trial , overall efficacy micafungin superior fluconazole antifungal prophylaxis neutropenic phase Allo-SCT . However , patient study receive CB transplant . This phase IIb , prospective , open-label , non-comparative study ass safety micafungin use prevention IFI neutropenic patient receive allo-SCT use CB source stem cell .</brief_summary>
	<brief_title>Antifungal Prophylaxis With Micafungin After Cord Blood Allogeneic Stem Cell Transplantation ( MycaCOORD )</brief_title>
	<detailed_description />
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Antifungal Agents</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Adult patient receive alloStem Cell Transplantation use Cord Blood source stem cell ( cf condition regimen recommendation ) . Sex male female Age 18 65 year time signing informed consent form . Diagnosis hematologic disease allograft decision take ( HLA ) match related unrelated donor within two month complete remission achievement Able understand voluntarily sign informed consent form . Subjects affiliated appropriate social security system Male , female without childbearing potential negative urine pregnancy test screen visit prior begin treatment . Women childbearing potential must follow adequate contraceptive measure . Men must agree use acceptable method contraception ( female partner ) duration study Each subject weigh 40 kg Any suspect documented invasive fungal infection study entry time prior study entry Use systemic antifungal therapy within 72 hour prior study entry Known history allergy , hypersensitivity intolerance echinocandin agent Patient medical , psychological social condition , opinion investigator could increase risk patient , decrease chance obtain satisfactory data achieve objective study . Participation study test new drug new conditioning HIV , HBV HCV positive Pregnant breast feeding female . Subject protect law .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Adult</keyword>
	<keyword>allo-Stem Cell Transplantation</keyword>
	<keyword>Cord Blood</keyword>
</DOC>